These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 30033421)

  • 21. Identification of a single time-point for plasma lansoprazole measurement that adequately reflects area under the concentration-time curve.
    Niioka T; Yasui-Furukori N; Uno T; Sugawara K; Kaneko S; Tateishi T
    Ther Drug Monit; 2006 Jun; 28(3):321-5. PubMed ID: 16778714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Formation of omeprazole sulphone but not 5-hydroxyomeprazole is inhibited by grapefruit juice.
    Tassaneeyakul W; Vannaprasaht S; Yamazoe Y
    Br J Clin Pharmacol; 2000 Feb; 49(2):139-44. PubMed ID: 10671908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.
    Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
    Eur J Clin Pharmacol; 2004 Nov; 60(9):623-8. PubMed ID: 15448955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. No influence of the CYP2C19-selective inhibitor omeprazole on the pharmacokinetics of the dopamine receptor agonist rotigotine.
    Elshoff JP; Cawello W; Andreas JO; Braun M
    Clin Pharmacol Drug Dev; 2014 May; 3(3):187-93. PubMed ID: 27128608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The (R)-omeprazole hydroxylation index reflects CYP2C19 activity in healthy Japanese volunteers.
    Yamada S; Shiohira H; Yasui-Furukori N; Tateishi T; Akamine Y; Uno T
    Eur J Clin Pharmacol; 2013 Jul; 69(7):1423-8. PubMed ID: 23435615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of allicin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes.
    Yang LJ; Fan L; Liu ZQ; Mao YM; Guo D; Liu LH; Tan ZR; Peng L; Han CT; Hu DL; Wang D; Zhou HH
    Eur J Clin Pharmacol; 2009 Jun; 65(6):601-8. PubMed ID: 19172254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects.
    Sakai T; Aoyama N; Kita T; Sakaeda T; Nishiguchi K; Nishitora Y; Hohda T; Sirasaka D; Tamura T; Tanigawara Y; Kasuga M; Okumura K
    Pharm Res; 2001 Jun; 18(6):721-7. PubMed ID: 11474773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19.
    Kim KA; Shon JH; Park JY; Yoon YR; Kim MJ; Yun DH; Kim MK; Cha IJ; Hyun MH; Shin JG
    Clin Pharmacol Ther; 2002 Jul; 72(1):90-9. PubMed ID: 12152007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment.
    Rost KL; Brockmöller J; Esdorn F; Roots I
    J Hepatol; 1995 Sep; 23(3):268-77. PubMed ID: 8550990
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose omeprazole: use of a multiple-dose study design to assess bioequivalence and accuracy of CYP2C19 phenotyping.
    Kovacs P; Edwards DJ; Lalka D; Scheiwe WM; Stoeckel K
    Ther Drug Monit; 1999 Oct; 21(5):526-31. PubMed ID: 10519449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers.
    Calabresi L; Pazzucconi F; Ferrara S; Di Paolo A; Tacca MD; Sirtori C
    Pharmacol Res; 2004 May; 49(5):493-9. PubMed ID: 14998561
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigation of the in vivo activity of CYP3A in Brazilian volunteers: comparison of midazolam and omeprazole as drug markers.
    Rocha A; Coelho EB; Moussa SA; Lanchote VL
    Eur J Clin Pharmacol; 2008 Sep; 64(9):901-6. PubMed ID: 18581106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19.
    Rost KL; Roots I
    Hepatology; 1996 Jun; 23(6):1491-7. PubMed ID: 8675169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CYP2C19 haplotypes in Koreans as a marker of enzyme activity evaluated with omeprazole.
    Jin SK; Kang TS; Eom SO; Kim JI; Lee HJ; Roh J
    J Clin Pharm Ther; 2009 Aug; 34(4):437-46. PubMed ID: 19583677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Omeprazole treatment of Korean patients: effects on gastric pH and gastrin release in relation to CYP2C19 geno- and phenotypes.
    Roh HK; Kim PS; Lee DH; Tybring G; Sagar M; Park CS; Seensalu R; Bertilsson L
    Basic Clin Pharmacol Toxicol; 2004 Sep; 95(3):112-9. PubMed ID: 15447734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of elagolix on the pharmacokinetics of omeprazole and its metabolites in healthy premenopausal women.
    Nader A; Mostafa NM; Kim E; Shebley M
    Clin Transl Sci; 2022 May; 15(5):1269-1280. PubMed ID: 35137535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Artemisinin induces omeprazole metabolism in human beings.
    Svensson US; Ashton M; Trinh NH; Bertilsson L; Dinh XH; Nguyen VH; Nguyen TN; Nguyen DS; Lykkesfeldt J; Le DC
    Clin Pharmacol Ther; 1998 Aug; 64(2):160-7. PubMed ID: 9728896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CYP2C19 genotypes and omeprazole metabolism after single and repeated dosing when combined with clarithromycin.
    Zhou Q; Yamamoto I; Fukuda T; Ohno M; Sumida A; Azuma J
    Eur J Clin Pharmacol; 1999 Mar; 55(1):43-7. PubMed ID: 10206083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Application of Microdosed Intravenous Omeprazole to Determine Hepatic CYP2C19 Activity.
    Mahmoudi M; Foerster KI; Burhenne J; Weiss J; Mikus G; Haefeli WE
    J Clin Pharmacol; 2021 Jun; 61(6):789-798. PubMed ID: 33236774
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolism of omeprazole after two oral doses in children 1 to 9 months old.
    Hoyo-Vadillo C; Venturelli CR; González H; Romero E; Cervantes R; Mata N; Ortiz AC; Rincón V; Zarate F; Sosa C; Ramírez-Mayans J
    Proc West Pharmacol Soc; 2005; 48():108-9. PubMed ID: 16416673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.